by Lew Rockwell, Lew Rockwell:

An “urgent notice” from the Wuhan. China Health Commission warning of “successive cases of unknown pneumonia” was also leaked and posted online on 30 December 2019. The statement ordered hospitals to “strengthen responsible leadership” and ensure that no one “disclose information to the public without authorization.” Under growing pressure regarding this “unknown pneumonia”, the following day the Health Commission said researchers were investigating 27 cases of viral pneumonia, its first official notice. How did they know it was a virus? They didn’t.

The BCG vaccine has been used for nearly 100 years in the battle against tuberculosis. BCG is thinned-out bovine (cattle) tuberculosis derived from the pathogen Mycobacterium bovis. It is also the only approved vaccination for TB in the world.

Bacille Calmette-Guérin (BCG) is a live strain of Mycobacterium bovis developed by Calmette and Guérin for use as an attenuated vaccine to prevent tuberculosis (TB) and other mycobacterial infections. The vaccine was first administered to humans in 1921 and remains the only vaccine against TB in general use.

BCG vaccine is the most widely administered vaccine in the world; it has been given to over three billion individuals, principally in the setting of routine newborn immunization.

CLAIM: BCG VACCINE “TRAINS” THE IMMUNE SYSTEM

But unlike recent claims that BCG will “train” the immune system to protect against COVID-19 or any other virus, the fact remains virtually any prior mycobacterial infection (whether naturally acquired or vaccine induced) appears to produce some level of protection against subsequent disease due to TB and, in some cases, to other mycobacteria, such as avium or fowl tuberculosis [Mycobacterium avium].

Natural infections that confer protection against TB include prior contained infection with Mycobacterium tuberculosis itself or prior infection with nontuberculous mycobacteria.

These observations suggest that protection is conferred by the immune response to common mycobacterial antigens from the mycobacteria inside the BCG vaccine which have nothing to do with a virus.

The case for the mycobacterial origins for COVID-19 has already been laid out. Such mycobacterial illness usually begins with flu-like symptoms indistinguishable from coronavirus and should be ruled out before pursuing a viral origin, as documented in a series of authoritative reports by Lawrence Broxmeyer MD.

Broxmeyer, L, Questions Raised By the New Coronavirus: Too Many Experts Too Little Thought.  Pulmonary Research and Respiratory Care, Vol. 4, Issue 1, 2020.
Broxmeyer, L, Sardi, B.  Why are Antibiotics & Not Anti-Virals Quelling the COVID-19 Coronavirus? Is It Really A Virus?  LewRockwell.com, March 2, 2020.
Broxmeyer, L.  Italy in Crisis, Pulmonary Research & Respiratory Care, 4 (1), 2020.
Broxmeyer, L. Promising antimicrobial hope for coronavirus but is it working against a virus? Pulmonary Research & Respiratory Care, 2020.
Sardi, B.  Further evidence tuberculosis bacterium masquerades as COVID-19 coronavirus. Academia.edu, 2020.

Trials Underway

Although COVID trials using BCG have started in the Netherlands, Germany, Denmark, U.S., Egypt and the UK, the Australian arm of the trial will be one of the largest, where 4,000 healthcare workers, doctors and nurses will participate, half of them getting the vaccine and the other half not getting it. Healthcare workers and the elderly are particularly vulnerable to infection and many, many of them have fallen sick or worse from “the virus.” It is projected that some sign of the effectiveness of giving this vaccination designed to combat tuberculosis will be in evidence by 3 months into this study’s trials, with researchers claiming that the vaccine works by somehow “boosting the body’s immune system.”

Read More @ LewRockwell.com